Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1988 1
1989 1
1990 3
1993 1
1994 2
1995 2
1996 1
1997 1
1998 3
1999 4
2000 3
2001 4
2002 10
2003 7
2005 7
2006 4
2007 1
2008 3
2009 3
2010 4
2011 4
2012 2
2013 4
2014 7
2015 6
2016 2
2017 5
2018 5
2019 4
2020 3
2021 2
2022 5
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

104 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Acute Myelomonocytic Leukemia"
Page 1
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. DiNardo CD, et al. Lancet Haematol. 2020 Oct;7(10):e724-e736. doi: 10.1016/S2352-3026(20)30210-6. Epub 2020 Sep 5. Lancet Haematol. 2020. PMID: 32896301 Free PMC article. Clinical Trial.
BACKGROUND: Venetoclax combined with hypomethylating agents is a new standard of care for newly diagnosed patients with acute myeloid leukaemia (AML) who are 75 years or older, or unfit for intensive chemotherapy. ...The study enrolled older patients (aged >60 years) wi …
BACKGROUND: Venetoclax combined with hypomethylating agents is a new standard of care for newly diagnosed patients with acute myeloid …
Extramedullary Manifestations of Myeloid Neoplasms.
Wilson CS, Medeiros LJ. Wilson CS, et al. Am J Clin Pathol. 2015 Aug;144(2):219-39. doi: 10.1309/AJCPO58YWIBUBESX. Am J Clin Pathol. 2015. PMID: 26185307 Review.
METHODS: We divided the submitted cases into four subgroups: (1) isolated myeloid sarcoma (MS); (2) MS with concurrent acute myeloid leukemia (AML), with a focus on karyotypic and molecular findings; (3) extramedullary relapse of AML, including relapse in the posttr …
METHODS: We divided the submitted cases into four subgroups: (1) isolated myeloid sarcoma (MS); (2) MS with concurrent acute myeloid …
Acute myeloid leukemia with t(8;16)(p11.2;p13.3)/KAT6A-CREBBP in adults.
Xie W, Hu S, Xu J, Chen Z, Medeiros LJ, Tang G. Xie W, et al. Ann Hematol. 2019 May;98(5):1149-1157. doi: 10.1007/s00277-019-03637-7. Epub 2019 Feb 13. Ann Hematol. 2019. PMID: 30759270 Clinical Trial.
t(8;16)(p11.2;p13.3)/KAT6A-CREBBP is a rare recurrent cytogenetic abnormality associated with acute myeloid leukemia (AML). ...We conclude that t(8;16)(p11.2;p13.3) commonly exhibits monoblastic or myelomonocytic differentiation and commonly arises in …
t(8;16)(p11.2;p13.3)/KAT6A-CREBBP is a rare recurrent cytogenetic abnormality associated with acute myeloid leukemia (A …
Acute Myeloid Leukemia With Recurrent Genetic Abnormalities Other Than Translocations.
Lin P, Falini B. Lin P, et al. Am J Clin Pathol. 2015 Jul;144(1):19-28. doi: 10.1309/AJCP97BJBEVZEUIN. Am J Clin Pathol. 2015. PMID: 26071459 Review.
OBJECTIVES: Session 2 of the workshop focused on cases of acute myeloid leukemia (AML) with gene mutations in the setting of a normal karyotype. ...RESULTS: We explored prognostic implications of gene mutations such as DNMT3A, issues related to the classification of …
OBJECTIVES: Session 2 of the workshop focused on cases of acute myeloid leukemia (AML) with gene mutations in the setting of a …
GATA2 deficiency and related myeloid neoplasms.
Wlodarski MW, Collin M, Horwitz MS. Wlodarski MW, et al. Semin Hematol. 2017 Apr;54(2):81-86. doi: 10.1053/j.seminhematol.2017.05.002. Epub 2017 May 10. Semin Hematol. 2017. PMID: 28637621 Free PMC article.
The common clinical denominator in all reported cohorts is the propensity for myeloid neoplasia (myelodysplastic syndrome [MDS], myeloproliferative neoplasms [MPN], chronic myelomonocytic leukemia [CMML], acute myeloid leukemia [AML]) with an overall p …
The common clinical denominator in all reported cohorts is the propensity for myeloid neoplasia (myelodysplastic syndrome [MDS], myeloprolif …
Myeloid neoplasms with t(12;22)(p13;q12)/MN1-EVT6: a systematic review of 12 cases.
Shao H, Cen J, Chen S, Qiu H, Pan J. Shao H, et al. Ann Hematol. 2018 Mar;97(3):417-424. doi: 10.1007/s00277-017-3208-2. Epub 2017 Dec 22. Ann Hematol. 2018. PMID: 29273914 Review.
In this study, we analyzed the clinical, cytogenetic, and molecular features of five new patients with the t(12;22)/MN1-EVT6 who presented with acute myeloid leukemia or chronic myelomonocytic leukemia. We subsequently reviewed the literature and ident …
In this study, we analyzed the clinical, cytogenetic, and molecular features of five new patients with the t(12;22)/MN1-EVT6 who presented w …
Classification of myeloid neoplasms: a comparative review.
McManus PM. McManus PM. Vet Clin Pathol. 2005 Sep;34(3):189-212. doi: 10.1111/j.1939-165x.2005.tb00042.x. Vet Clin Pathol. 2005. PMID: 16134066 Review.
WHO revisions lower the blast threshold from 30% to 20% for diagnosing acute myeloid leukemia (AML) and expand and redefine AML categories. ...That threshold is 50% for diagnosing AML with multilineage dysplasia. Chronic myelomonocytic leukemia has bee …
WHO revisions lower the blast threshold from 30% to 20% for diagnosing acute myeloid leukemia (AML) and expand and redefine AM …
Low IL7R Expression at Diagnosis Predicted Relapse in Adult Acute Myeloid Leukemia Patients With t(8;21).
Xu N, Sun K, Wang YZ, Chen WM, Wang J, Li LD, Wang X, Hao Y, Chang Y, Liu YR, Huang XJ, Qin YZ. Xu N, et al. Front Immunol. 2022 Jul 7;13:909104. doi: 10.3389/fimmu.2022.909104. eCollection 2022. Front Immunol. 2022. PMID: 35874754 Free PMC article.
BACKGROUND: Acute myeloid leukemia (AML) with t(8;21) needs to be further stratified. ...IL7R is reported to be relevant to prognosis in solid tumor and acute lymphoblastic leukemia. However, the prognostic significance of IL7R in t(8;21) AML remains t …
BACKGROUND: Acute myeloid leukemia (AML) with t(8;21) needs to be further stratified. ...IL7R is reported to be relevant to pr …
Recurrent somatic JAK-STAT pathway variants within a RUNX1-mutated pedigree.
Tawana K, Wang J, Király PA, Kállay K, Benyó G, Zombori M, Csomor J, Al Seraihi A, Rio-Machin A, Matolcsy A, Chelala C, Cavenagh J, Fitzgibbon J, Bödör C. Tawana K, et al. Eur J Hum Genet. 2017 Aug;25(8):1020-1024. doi: 10.1038/ejhg.2017.80. Epub 2017 May 17. Eur J Hum Genet. 2017. PMID: 28513614 Free PMC article.
Germline variants within the transcription factor RUNX1 are associated with familial platelet disorder and acute leukemia in over 40% of carriers. At present, the somatic events triggering leukemic transformation appear heterogeneous and profiles of leukemia …
Germline variants within the transcription factor RUNX1 are associated with familial platelet disorder and acute leukemia in o …
The genomic landscape of juvenile myelomonocytic leukemia.
Stieglitz E, Taylor-Weiner AN, Chang TY, Gelston LC, Wang YD, Mazor T, Esquivel E, Yu A, Seepo S, Olsen S, Rosenberg M, Archambeault SL, Abusin G, Beckman K, Brown PA, Briones M, Carcamo B, Cooper T, Dahl GV, Emanuel PD, Fluchel MN, Goyal RK, Hayashi RJ, Hitzler J, Hugge C, Liu YL, Messinger YH, Mahoney DH Jr, Monteleone P, Nemecek ER, Roehrs PA, Schore RJ, Stine KC, Takemoto CM, Toretsky JA, Costello JF, Olshen AB, Stewart C, Li Y, Ma J, Gerbing RB, Alonzo TA, Getz G, Gruber T, Golub T, Stegmaier K, Loh ML. Stieglitz E, et al. Nat Genet. 2015 Nov;47(11):1326-1333. doi: 10.1038/ng.3400. Epub 2015 Oct 12. Nat Genet. 2015. PMID: 26457647 Free PMC article.
Juvenile myelomonocytic leukemia (JMML) is a myeloproliferative neoplasm (MPN) of childhood with a poor prognosis. ...We therefore sought to genomically characterize serial samples from patients at diagnosis through relapse and transformation to acute myeloid …
Juvenile myelomonocytic leukemia (JMML) is a myeloproliferative neoplasm (MPN) of childhood with a poor prognosis. ...We there …
104 results